معرفی
Sarah Gooding is a Clinician Scientist at the University of Oxford, affiliated with the Chapman Group (Recombination Mechanisms in Immunity and Cancer) since 2021. She also holds an honorary consultant role in the Oxford University Hospitals Haematology Department. Her research bridges clinical practice and genomics to address multiple myeloma's drug resistance and poor patient outcomes, with a focus on genomic instability and clonal evolution.
- Academic Rank: Physician Scientist
- Key Institutions: University of Oxford (WIMM), Oxford University Hospitals
- Research Themes: Cancer Genomics, Precision Medicine, Bone Marrow Microenvironment, Immune Interactions
Her work integrates genetic analysis and transcriptomic profiling to uncover mechanisms of resistance to therapies like IMiDs and proteasome inhibitors, aiming to improve patient survival through personalized treatment strategies. Recent publications highlight her contributions to targeted sequencing, organoid modeling, and BMP signaling inhibition in myeloma.
Despite her impactful research, no specific scientific awards are mentioned in the provided text. She has not been associated with formal student advising roles, though her leadership in clinical trials (e.g., TREATT) and multiomics platforms underscores her collaborative and translational approach.
